Your AI-Trained Oncology Knowledge Connection!
Patients <70 years old with chronic lymphocytic leukemia treated in the minimal residual disease (MRD)–cohort of the phase II CAPTIVATE trial had undetectable MRD rates of 75% and 72% in the peripheral blood and bone marrow, respectively, with the frontline combination of ibrutinib and venetoclax, according to findings presented at the 2019 ASH Annual Meeting.
Jacqueline C. Barrientos, MD, MS, discusses exciting novel combination strategies that are being presented at the 2019 ASH Annual meeting.
Patients with refractory large B-cell lymphoma who were treated with Axi-cel had a 3-year overall survival rate of 47%, according to an updated analysis of the phase II ZUMA-1 trial.
Complete remissions were achieved in greater than 20% of patients with highly refractory non-Hodgkin lymphomas who had been previously been treated with chimeric antigen receptor T-cell therapy with Mosunetuzumab, a novel bispecific antibody, according to study results presented at the 2019 American Society of Hematology Annual Meeting.
Patients with treatment-naïve chronic lymphocytic leukemia experienced a statistically significant improvement in progression-free survival with acalabrutinib as a single agent or in combination with obinutuzumab when compared with obinutuzumab plus chlorambucil, according to results from the phase III ELEVATE-TN trial presented at the 2019 ASH Annual Meeting.
Encouraging signs of dose-dependent efficacy, as well as a promising safety profile, were observed in patients with heavily pretreated relapsed/refractory multiple myeloma who were treated with CC-93269, a human IgG1-based T-cell engager that binds to BCMA and CD3 epsilon in a 2+1 format.
Patients with a difficult-to-treat form of multiple myeloma who were treated with a novel, bispecific anti-BCMA/anti-CD38 chimeric antigen receptor (CAR) T-cell therapy experienced promising responses and a manageable safety profile, according to results of a study that were presented at the 61st Annual American Society of Hematology Annual Meeting and Exposition.<br />
A multi-antigen off-the-shelf chimeric antigen receptor natural killer cell therapy has been included in the ASH annual meeting spotlight due to exciting preclinical evidence. An investigational new drug application was approved in September 2019 for the therapy, labeled as FT596, developed by Fate Therapeutics, and human trials are scheduled to start in the first quater of 2020.
According to the phase III MAIA trial, triplet regimen daratumumab, lenalidomide, plus dexamethasone reduced risk of disease progression or death by 44% in newly diagnosed patients with multiple myeloma who were not candidates for high-dose chemotherapy and autologous stem-cell transplant, compared to patients who received lenalidomide plus dexamethasone.
An overall response rate of 26.2% was induced by selinexor, an oral XPO1 inhibitor, combination in heavily pretreated patients with penta-refractory multiple myeloma. According to the findings from part 2 of the pivotal STORM trial, selinexor is now the first investigational oral therapy to show activity in these patients.
An update on the pivotal phase III QuANTUM-R study presented at the 2018 ASH Annual Meeting demonstrated overall survival benefit across patient subgroups with quizartinib in patients with relapsed/refractory <em>FLT3</em>-ITD–mutated acute myeloid leukemia.
A significant reduction in the risk of disease progression or death was observed from treatment with the upfront combination of ibrutinib plus obinutuzumab in patients with chronic lymphocytic leukemia and small lymphocytic lymphoma compared with chlorambucil and obinutuzumab.
Durable responses were achieved with acalabrutinib therapy for patients with relapsed/refractory mantle cell lymphoma, with 40% still on treatment for more than 2 years, according to long-term follow-up findings presented at the 2018 ASH Annual Meeting.
Initial results from a phase I study showed an objective response rate of 83.3% had been achieved in heavily pretreated patients with relapsed/refractory multiple myeloma who had been treated with the anti-BCMA CAR T-cell therapy bb21217.
Maria-Victoria Mateos, MD, PhD, discusses the key takeaways from the phase III ALCYONE trial looking at bortezomib, melphalan, and prednisone in combination with daratumumab in patients with newly diagnosed multiple myeloma who are transplant ineligible.
According to a presentation of findings from the phase II CLARITY study at the 2018 ASH Annual Meeting, ibrutinib in combination with venetoclax demonstrated tolerability among patients with relapsed/refractory chronic lymphocytic leukemia. The combination also induced minimal residual disease negativity in the marrow in 39% of these patients after 12 months.
Among older patients with acute myeloid leukemia who were ineligible for intensive chemotherapy, preliminary findings demonstrated that more than 70% achieved complete responses to venetoclax in combination with hypomethylating agents.
According to findings from the phase III TOURMALINE-MM3, a 39% improvement in progression-free survival was demonstrated with 2-year maintenance therapy with ixazomib compared with placebo for patients with newly diagnosed multiple myeloma who had previously achieved a partial response with an induction therapy of a proteasome inhibitor and/or an immunomodulatory agent following autologous stem cell transplant.
Peter M. Voorhees, MD, investigator, department of hematologic oncology & blood disorders, Levine Cancer Institute/Atrium Health, discusses efficacy and updated safety findings of a safety run-in cohort from the phase II Griffin trial, a randomized study of daratumumab, bortezomib, lenalidomide, and dexamethasone (Dara-Vrd) versus Vrd in patients with newly diagnosed multiple myeloma eligible for high-dose therapy and autologous stem cell transplantation, during the 2018 ASH Annual Meeting.
It may be possible for hematologists to determine subtypes of acute myeloid leukemia based on genetic analsysis of blood samples in 7 days or less. According to Amy Burd, PhD, this process could play an important role in diagnosing and treating patients.
Pembrolizumab in combination with umbralisib and ublituximab induced responses in 90% of patients with relapsed/refractory chronic lymphocytic leukemia, according to data from a phase I/II study presented at the 2018 ASH Annual Meeting. Additionally, a 50% response rate was also demonstrated in patients with Richter’s transformation.
After 7 years of follow-up, single-agent ibrutinib demonstrated continued efficacy in the frontline and heavily pretreated, relapsed/refractory settings for patients with chronic lymphocytic leukemia and small lymphocytic lymphoma.
Lisocabtagene maraleucel induced an 81.3% best overall response rate and 43.8% complete response in high-risk patients with chronic lymphocytic leukemia who were heavily pretreated and had previously received ibrutinib, according to dose-finding results presented at the 2018 ASH Annual Meeting.
Zanubrutinib induced an overall response rate of 83.5% in patients with relapsed/refractory mantle cell lymphoma, with many responses demonstrating durability, according to the results of a phase II trial.<br />
According to results from a small clinical study, checkpoint inhibitors in combination with chimeric antigen receptor T-cell therapy showed promise for improving CAR T-cell persistance in some patients with relapsed B-cell acute lymphoblastic leukemia. <br />
In a study of transplant-eligible patients with newly diagnosed multiple myeloma, daratumumab added to bortezomib, lenalidomide, and dexamethasone induced at least a very good partial response in all patients, including a complete response in 63% of patients, at the end of consolidation therapy.<br />
Patients with acute lymphoblastic leukemia saw a reduction in the risk for recurrence after receiving a stem cell transplant for the first time following treatment with CD19 chimeric antigen receptor T-cell therapy.
According to a retrospective phase I/II study, over 80% of patients with relapsed or refractory chronic lymphocytic leukemia responded to concurrent treatment with ibrutinib and the CD19-targeted chimeric antigen receptor CAR T-cell therapy, JCAR014.<sup>1</sup> Findings from this study were presented at the 60th American Society of Hematology Annual Meeting.
The need for frequent red blood cell transfusions was reduced with luspatercept in nearly 53% of patients with anemia associated with low- to intermediate-risk myelodysplastic syndrome.
Victor Chow, MD, senior hematology-oncology fellow, University of Washington, Fred Hutchinson Cancer Research Center, Seattle Cancer Care Alliance, discusses a retrospective study assessing outcomes of patients with large B-cell lymphomas and progressive disease following CD19-Specific CAR T-cell therapy during the 2018 ASH Annual Meeting.